{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T23:58:06Z","timestamp":1775519886677,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sanofi Saudi Arabia"},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011665","name":"Deanship of Scientific Research, King Saud University","doi-asserted-by":"publisher","award":["1435-024"],"award-info":[{"award-number":["1435-024"]}],"id":[{"id":"10.13039\/501100011665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clml.2025.05.005","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T17:35:15Z","timestamp":1746725715000},"page":"e756-e765","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Guidelines on Management of Multiple Myeloma in the Relapsed\/Refractory Setting: The Saudi Myeloma Working Group Guideline"],"prefix":"10.1016","volume":"25","author":[{"given":"Ayman","family":"Alhejazi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6902-1876","authenticated-orcid":false,"given":"Ghazi S.","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah S. Al","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majed","family":"Alahmadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibraheem","family":"Motabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahad Z.","family":"Alsharif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Alamer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Abduljalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imran","family":"Tailor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Marei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed S.","family":"Barefah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansour","family":"Aljabry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saud","family":"Alhayli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binyam","family":"Usman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr","family":"Hanbali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal","family":"Alabdulwahab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ihab","family":"ElHemaidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hatem Mahmoud","family":"Alahwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enas","family":"Mutahar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1711-7013","authenticated-orcid":false,"given":"Ahmad","family":"Alsaeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clml.2025.05.005_bib0001","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2025.05.005_bib0002","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2011","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2025.05.005_bib0003","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.3390\/curroncol30020179","article-title":"Relapsed\/refractory multiple myeloma: a review of available therapies and clinical scenarios encountered in myeloma relapse","volume":"30","author":"Bhatt","year":"2023","journal-title":"Curr Oncol"},{"issue":"3","key":"10.1016\/j.clml.2025.05.005_bib0004","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the international myeloma working group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.05.005_bib0005","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41408-022-00695-5","article-title":"Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: consensus recommendations of the NCI multiple myeloma steering committee","volume":"12","author":"Kumar","year":"2022","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.clml.2025.05.005_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051558","article-title":"Novel agents as main drivers for continued improvement in survival in multiple myeloma","volume":"15","author":"Puertas","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.clml.2025.05.005_bib0007","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the Global burden of disease Study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2025.05.005_bib0008","article-title":"Supportive care in multiple myeloma: current practices and advances","volume":"29","author":"Miceli","year":"2021","journal-title":"Cancer Treat Res Commun"},{"issue":"22","key":"10.1016\/j.clml.2025.05.005_bib0009","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1002\/cncr.32428","article-title":"Underutilization of guideline-recommended supportive care among older adults with multiple myeloma in the United States","volume":"125","author":"Giri","year":"2019","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clml.2025.05.005_bib0010","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1182\/blood-2018-99-119791","article-title":"Racial disparities in the utilization of recommended supportive care among patients with Multiple myeloma in the United States","volume":"132","author":"Giri","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.05.005_bib0011","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4103\/joah.joah_62_18","article-title":"Multiple myeloma in Saudi Arabia: consensus of the Saudi lymphoma\/myeloma group","volume":"10","author":"Alaskar","year":"2019","journal-title":"Journal of Applied Hematol"},{"issue":"6","key":"10.1016\/j.clml.2025.05.005_bib0012","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/bloodadvances.2022007082","article-title":"Outcomes after biochemical or clinical progression in patients with multiple myeloma","volume":"7","author":"Goldman-Mazu","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.clml.2025.05.005_bib0013","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.clml.2025.05.005_bib0014","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.05.005_bib0015","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.05.005_bib0016","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.05.005_bib0017","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clml.2025.05.005_bib0018","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-019-0187-7","article-title":"The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG)","volume":"9","author":"Kyriakou","year":"2019","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.clml.2025.05.005_bib0019","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.annonc.2020.07.003","article-title":"Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up","volume":"31","author":"Jordan","year":"2020","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.clml.2025.05.005_bib0020","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","article-title":"Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group","volume":"22","author":"Terpos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.clml.2025.05.005_bib0021","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clml.2025.05.005_bib0022","unstructured":"NCCN. Multiple myeloma. Accessed: January 27, 2025. https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/myeloma-patient.pdf"},{"key":"10.1016\/j.clml.2025.05.005_bib0023","unstructured":"Clinical Practice Guidelines on Supportive Care. Accessed: January 27, 2025. https:\/\/www.esmo.org\/guidelines\/guidelines-by-topic\/esmo-clinical-practice-guidelines-supportive-and-palliative-care"},{"issue":"2","key":"10.1016\/j.clml.2025.05.005_bib0024","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/bjh.17410","article-title":"Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology\/UK Myeloma Forum Guideline","volume":"193","author":"Sive","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.05.005_bib0025","unstructured":"Development and Update of Guidelines. Accessed: January 27, 2025. https:\/\/www.nccn.org\/guidelines\/guidelines-process\/development-and-update-of-guidelines"},{"key":"10.1016\/j.clml.2025.05.005_bib0026","unstructured":"Sch\u00fcnemann H, Bro\u017cek NJ, Guyatt G, Oxman A. GRADE handbook. Accessed: January 27, 2025. https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html"},{"issue":"2","key":"10.1016\/j.clml.2025.05.005_bib0027","doi-asserted-by":"crossref","first-page":"128","DOI":"10.7326\/M16-1565","article-title":"A reporting tool for practice guidelines in health care: the right statement","volume":"166","author":"Chen","year":"2017","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.clml.2025.05.005_bib0028","doi-asserted-by":"crossref","first-page":"67","DOI":"10.46989\/001c.92555","article-title":"Epidemiology, treatment trends, and outcomes of Multiple myeloma in the Middle East and Africa: a systematic review","volume":"6","author":"Mattar","year":"2024","journal-title":"Clin Hematol Int"},{"key":"10.1016\/j.clml.2025.05.005_bib0029","unstructured":"Multiple myeloma in Saudi Arabia: a comprehensive literature review | International Journal of Medicine in Developing Countries. Accessed: January 27, 2025. https:\/\/ijmdc.com\/?mno=128537"},{"issue":"4","key":"10.1016\/j.clml.2025.05.005_bib0030","doi-asserted-by":"crossref","first-page":"198","DOI":"10.5144\/0256-4947.2021.198","article-title":"Outcomes of autologous stem cell transplantation for multiple myeloma in Saudi Arabia","volume":"41","author":"Abdrabou","year":"2021","journal-title":"Ann Saudi Med"},{"issue":"21","key":"10.1016\/j.clml.2025.05.005_bib0031","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1182\/blood.V124.21.5995.5995","article-title":"Retrospective observational study on multiple myeloma cases admitted to Kfsh \u2013 Dammam between 1st of June 2006 till the end of December 2013","volume":"124","author":"Abduljalil","year":"2014","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.clml.2025.05.005_bib0032","article-title":"P904: locommotion: a prospective, observational, multinational study of real-life current standards of care in patients with relapsed\/refractory multiple myeloma\u2013 FINAL analysis AT 2-year follow-up","volume":"7","author":"Moreau","year":"2023","journal-title":"Hemasphere"},{"issue":"2","key":"10.1016\/j.clml.2025.05.005_bib0033","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/10428194.2020.1827253","article-title":"Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011-2019 oncology clinic electronic health record data","volume":"62","author":"Braunlin","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.clml.2025.05.005_bib0034","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.clml.2025.05.005_bib0035","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin Proc"},{"issue":"18","key":"10.1016\/j.clml.2025.05.005_bib0036","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.005_bib0037","unstructured":"Treatment Guidelines \u2014 mSMART. Accessed: January 27, 2025. https:\/\/www.msmart.org\/mm-treatment-guidelines"},{"issue":"12","key":"10.1016\/j.clml.2025.05.005_bib0038","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.clml.2025.05.005_bib0039","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.05.005_bib0040","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/ajh.26269","article-title":"Venetoclax for the treatment of multiple myeloma: outcomes outside of clinical trials","volume":"96","author":"Sidiqi","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.05.005_bib0041","series-title":"Patients With Relapsed\/Refractory Multiple Myeloma. 21st International Myeloma Society (IMS) Annual Meeting; September 25\u201328, 2024","article-title":"Long-term efficacy and safety results from the phase 1\/2 MonumenTAL-1 study of Talquetamab, a GPRC5D\u00d7CD3 bispecific antibody","author":"Schinke","year":"2024"},{"issue":"9","key":"10.1016\/j.clml.2025.05.005_bib0042","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/bloodadvances.2023012066","article-title":"Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma","volume":"8","author":"Reyes","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.05.005_bib0043","doi-asserted-by":"crossref","unstructured":"Jakubowiak A Updated results of Talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma with prior exposure to T-cell redirecting therapies: results of the phase 1\/2 MonumenTAL-1 study. Accessed: December 10, 2023. https:\/\/ashpublications.org\/blood\/article\/142\/Supplement%201\/3377\/502476\/Updated-Results-of-Talquetamab-a-GPRC5D-CD3.","DOI":"10.1182\/blood-2023-187242"},{"key":"10.1016\/j.clml.2025.05.005_bib0044","unstructured":"Teh BW, Slavin MA, Cooley L, et al. Consensus clinical practice guidelines for the prevention of infection in patients with Multiple Myeloma. 2022. Accessed: January 27, 2025. https:\/\/msmart-amyloidosis.squarespace.com\/s\/mSMART-Newly-Dx-v22-Oct-2024rev3.pdf"},{"key":"10.1016\/j.clml.2025.05.005_bib0045","unstructured":"Mayo. Mayo stratification for myelom a and risk-adapted therapy."}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:06:34Z","timestamp":1758603994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025001570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2152265025001570"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.05.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guidelines on Management of Multiple Myeloma in the Relapsed\/Refractory Setting: The Saudi Myeloma Working Group Guideline","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}